137 related articles for article (PubMed ID: 29373711)
1. Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma.
Giordano TJ; Haugen BR; Sherman SI; Shah MH; Caoili EM; Koenig RJ
J Clin Endocrinol Metab; 2018 Apr; 103(4):1277-1281. PubMed ID: 29373711
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.
Dobson ME; Diallo-Krou E; Grachtchouk V; Yu J; Colby LA; Wilkinson JE; Giordano TJ; Koenig RJ
Endocrinology; 2011 Nov; 152(11):4455-65. PubMed ID: 21952241
[TBL] [Abstract][Full Text] [Related]
3. Adipogenic Differentiation of Thyroid Cancer Cells Through the Pax8-PPARγ Fusion Protein Is Regulated by Thyroid Transcription Factor 1 (TTF-1).
Xu B; O'Donnell M; O'Donnell J; Yu J; Zhang Y; Sartor MA; Koenig RJ
J Biol Chem; 2016 Sep; 291(37):19274-86. PubMed ID: 27435678
[TBL] [Abstract][Full Text] [Related]
4. Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein.
Zhang Y; Yu J; Lee C; Xu B; Sartor MA; Koenig RJ
Oncotarget; 2015 Dec; 6(38):40418-32. PubMed ID: 26595524
[TBL] [Abstract][Full Text] [Related]
5. Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.
Zhang Y; Yu J; Grachtchouk V; Qin T; Lumeng CN; Sartor MA; Koenig RJ
Oncotarget; 2017 Jan; 8(4):5761-5773. PubMed ID: 28008156
[TBL] [Abstract][Full Text] [Related]
6. In silico modeling of PAX8-PPARγ fusion protein in thyroid carcinoma: influence of structural perturbation by fusion on ligand-binding affinity.
Sakaguchi K; Okiyama Y; Tanaka S
J Comput Aided Mol Des; 2021 May; 35(5):629-642. PubMed ID: 33748935
[TBL] [Abstract][Full Text] [Related]
7. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma.
McIver B; Grebe SK; Eberhardt NL
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):221-34. PubMed ID: 15379724
[TBL] [Abstract][Full Text] [Related]
8. The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.
Vu-Phan D; Grachtchouk V; Yu J; Colby LA; Wicha MS; Koenig RJ
Endocr Relat Cancer; 2013 Oct; 20(5):725-39. PubMed ID: 24025583
[TBL] [Abstract][Full Text] [Related]
9. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
Giordano TJ; Au AY; Kuick R; Thomas DG; Rhodes DR; Wilhelm KG; Vinco M; Misek DE; Sanders D; Zhu Z; Ciampi R; Hanash S; Chinnaiyan A; Clifton-Bligh RJ; Robinson BG; Nikiforov YE; Koenig RJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1983-93. PubMed ID: 16609007
[TBL] [Abstract][Full Text] [Related]
10. Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice.
Diallo-Krou E; Yu J; Colby LA; Inoki K; Wilkinson JE; Thomas DG; Giordano TJ; Koenig RJ
Endocrinology; 2009 Nov; 150(11):5181-90. PubMed ID: 19797117
[TBL] [Abstract][Full Text] [Related]
11. In Silico Search for Drug Candidates Targeting the PAX8-PPARγ Fusion Protein in Thyroid Cancer.
Sakaguchi K; Okiyama Y; Tanaka S
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791384
[TBL] [Abstract][Full Text] [Related]
12. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.
Reddi HV; McIver B; Grebe SK; Eberhardt NL
Endocrinology; 2007 Mar; 148(3):932-5. PubMed ID: 16946003
[TBL] [Abstract][Full Text] [Related]
13. Pax-8-PPAR-γ fusion protein in thyroid carcinoma.
Raman P; Koenig RJ
Nat Rev Endocrinol; 2014 Oct; 10(10):616-23. PubMed ID: 25069464
[TBL] [Abstract][Full Text] [Related]
14. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy.
Reddi HV; Driscoll CB; Madde P; Milosevic D; Hurley RM; McDonough SJ; Hallanger-Johnson J; McIver B; Eberhardt NL
Cancer Gene Ther; 2013 May; 20(5):267-75. PubMed ID: 23598436
[TBL] [Abstract][Full Text] [Related]
15. The Putative PAX8/PPARγ Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPARγ Activity.
Reddi HV; Madde P; Milosevic D; Hackbarth JS; Algeciras-Schimnich A; McIver B; Grebe SK; Eberhardt NL
Genes Cancer; 2011 Jan; 2(1):46-55. PubMed ID: 21779480
[TBL] [Abstract][Full Text] [Related]
16. Thyroid-Specific PPARγ Deletion Is Benign in the Mouse.
Yu J; Koenig RJ
Endocrinology; 2018 Mar; 159(3):1463-1468. PubMed ID: 29420754
[TBL] [Abstract][Full Text] [Related]
17. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.
Eberhardt NL; Grebe SK; McIver B; Reddi HV
Mol Cell Endocrinol; 2010 May; 321(1):50-6. PubMed ID: 19883731
[TBL] [Abstract][Full Text] [Related]
18. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
Lado-Abeal J; Celestino R; Bravo SB; Garcia-Rendueles ME; de la Calzada J; Castro I; Castro P; Espadinha C; Palos F; Soares P; Alvarez CV; Sobrinho-Simões M; Cameselle-Teijeiro J
Endocr Relat Cancer; 2010 Sep; 17(3):599-610. PubMed ID: 20427420
[TBL] [Abstract][Full Text] [Related]
19. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].
Kroll TG; Sarraf P; Pecciarini L; Chen CJ; Mueller E; Spiegelman BM; Fletcher JA
Science; 2000 Aug; 289(5483):1357-60. PubMed ID: 10958784
[TBL] [Abstract][Full Text] [Related]
20. Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
